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Hope for the best, but expect the worst
Sadly, most patients who undergo successful resection of pancreatic adenocarcinoma (PAC) today still 
succumb to recurrent disease. Multimodality therapies offered before or after resections do not change this. 
Clinicians and patients enter diagnostic surveillance programs hoping to identify early recurrence, but to 
what end? Tzeng et al. from MD Anderson Cancer Center in Texas offer a retrospective analysis of one such 
program and evaluate its diagnostic yield. Of 327 patients with PAC who underwent pancreaticoduodenec-
tomy between 1998–2008, 66% (216) developed recurrence. In over one-half of these patients, these recur-
rences were identifi ed before the patients developed any symptoms at all. If symptoms had occurred by the 
time a recurrence was found, patients were more likely to suffer from advanced systemic disease and carci-
nomatosis and were much less likely to benefi t from additional therapy. While median times to recurrence 
did not differ between symptomatic and asymptomatic patients, the latter group was able to receive salvage 
therapy more often and reliably and they enjoyed at least some survival benefi t. But again, these patients 
were only 55% of the total cohort, indicating that disease biology, not careful surveillance was the determin-
ing factor. Any survival value for surveillance faded by two years and more after resection. Opponents of 
surveillance programs will cite the costs and resources allocated in delaying the inevitable for most resected 
PAC patients. Perhaps true, but this paper convinces me of their value, especially when recurrences are 
identifi ed before symptoms develop. Sadly for PAC, costs and allocated resources remain short-term 
considerations.
Mark Callery
Introduction of ‘on-demand’ antibiotics does not result in a change in 
outcome for those patients with severe acute pancreatitis
The role of antibiotics in severe acute pancreatitis (SAP) has been the subject of ongoing debate for many 
years. Despite several randomised trials, meta-analyses and recommendations as part of guidelines for the 
management of SAP, no fi rm consensus has been reached. In this issue of HPB, Ignatavicius et al. have 
retrospectively reviewed two consecutive cohorts of patients in which the approach to antibiotic usage 
changed from prophylaxis to ‘on-demand’ as the authors adopted recommendations from two meta-analyses 
published in 2006–2007. Throughout the study period both groups’ indication for intervention was the same 
and a step-up approach applied throughout. The key fi ndings of this study were that only 18.7% of patients 
in the ‘on-demand’ group received antibiotics as compared to 58% of patients in the prophylactic group 
who received greater than 14 days of antibiotics. There was no statistical difference in the frequency of 
multi-resistant organisms (although risk of type II error exists) but the frequency of fungal cultures was 
signifi cantly increased in those receiving prophylactic antibiotics. Overall there was a signifi cant reduction 
in overall interventions performed in the group who received prophylactic antibiotics but no individual 
intervention was signifi cantly reduced. Importantly, there was no statistical difference in the time to interven-
tion between the two groups but again the risk of type II error exists. No difference in mortality was observed. 
This study suffers from many of the problems that have plagued the randomised trials comparing the use 
of antibiotics in severe acute pancreatitis. Only 54% of all patients had greater than 30% necrosis, thus almost 
half of the patients in the study were unlikely to develop infected necrosis. Although power studies were 
done the multitude of primary endpoints and lack of clarity around the magnitude of difference being tested 
means that it is not clear whether a non signifi cant difference between the two groups truly represents no 
clinical difference. Additionally, those in the on-demand group were enrolled in a second parallel study which 
means that management between the two groups differed. So, what can be taken from this study? Firstly the 
authors should be congratulated on auditing a change in practice and secondly it is this reader’s conclusion, 
as a practitioner of the ‘on-demand’ approach, that it will require higher levels of evidence to result in con-
version to the use of prophylactic antibiotics in SAP.
Saxon Connor
Laparoscopic liver resection for adenoma
The drive to laparoscopic management of liver lesions continues in this issue in which Herman and his 
colleagues from Sao Paolo propose that laparoscopic resection should be the standard of care for hepatic 
adenoma. This conclusion is based on an experience with 29 patients undergoing three right hepatectomies, 
17 left lateral sectionectomies and 11 wedge or segmental resections. There was no need for transfusion or 
conversion to open surgery in this series. Hospital stay was less than four days on average and only two 
patients experienced complications. These are convincing data that equal the best reported to date but they 
have to be taken in context. This Brazilian group is experienced in laparoscopic hepatobiliary surgery and 
patients have been carefully selected with no apparent preoperative misdiagnosis. That said, we have no data 
regarding longer-term quality of life and several enhanced recovery programmes for open liver surgery would 
claim comparable postoperative outcomes. Finally, tucked away in the discussion, the authors summarise 
the advances in molecular profi ling of such lesions. Rather than resecting such benign lesions, it may be that 
there will be fewer that require any intervention! Before accepting the headline view, read the article.
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